Drugs / ALN-SOD
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06351592 | Aug 2024 → Mar 2032 expected | amyotrophic lateral sclerosis | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALN-SOD | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06351592 ↗ |
| Route | Intrathecal | “Intrathecally administered ALN-SOD” NCT06351592 ↗ |